Evidence map›Paper›PMID 40463522›Full record

ArticlemedRxiv : the preprint server for health sciences2025

IsomiR Utility in Amyotrophic Lateral Sclerosis Prognostication.

Yahel Cohen, Ilan Sinai, Iddo Magen, Yehuda Matan Danino, Joanne Wuu, Andrea Malaspina, Michael Benatar, Eran Hornstein

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yahel CohenDepartment ofMolecular Genetics, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-8628-5769
Ilan SinaiDepartment ofMolecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Iddo MagenDepartment ofMolecular Genetics, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-3011-3175
Yehuda Matan DaninoDepartment ofMolecular Genetics, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0001-5295-0487
Joanne WuuDepartment of Neurology and ALS Center, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0009-0005-9643-9855
Andrea MalaspinaUCL Queen Square Motor Neuron Disease Center, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, UK.ORCID 0000-0002-8020-7567
Michael BenatarDepartment of Neurology and ALS Center, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0003-4241-5135
Eran HornsteinDepartment ofMolecular Genetics, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-5534-1924

Funding

Uncovering new genes and disease modifiers for ALS and related disordersU54NS092091 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Michael Benatar · 2014 to 2026
$19.8M
Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)U01NS107027 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BENATAR, MICHAEL, MALASPINA, ANDREA · 2018 to 2023
$3.5M
NINDS NIH HHS U01 NS107027NINDS NIH HHS U54 NS092091
6 · The paper itself

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive motor neuron loss. IsomiRs are microRNA (miRNA) isoforms that arise from alternative processing or editing events during miRNA biogenesis. While isomiRs may carry distinct biological and clinical relevance, their potential as cell-free biomarkers in neurodegeneration remains largely unexplored. Method: Here we investigated the prognostic utility of plasma isomiRs in ALS, using next-generation sequencing and two orthogonal statistical approaches. Findings: We profiled cell-free isomiRs in 154 ALS patients from a British cohort and identified higher levels of one isomiR, let-7g-5p.t, to be associated with longer survival. This finding was independently validated in an international ALS cohort of 200 patients. let-7g-5p.t prognostic utility was comparable to that of neurofilament light chain (NfL) or miR-181. Conclusion: These results establish isomiRs as a novel class of blood-based biomarkers in ALS with potential to refine prognostication in clinical trials for neurodegenerative diseases. Funding: Target ALS, Israel Science Foundation (ISF 3497/21, 424/22) and the CReATe Consortium. All additional funding can be found in the Acknowledgements section of this paper.

Indexed as

Amyotrophic Lateral SclerosisisomiRsmachine learning in biomedicinemiRNAneurodegenerative diseasesPrognostic biomarkerssmall RNA biomarkerssurvival analysistranslational neuroscience

Identifiers

PMID40463522
PMCPMC12132153

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.